Stem cells

Global Hematopoietic Stem Cell Transplantation Market to 2027 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Health, Stem cells, Branches of biology, Medical specialties, Biology, Stem cells, Hematology, Transplantation medicine, Surgical oncology, Lymphology, Hematopoietic stem cell transplantation, Hematopoietic stem cell, Bone marrow, HSCT

The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma.
  • Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient.
  • Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis.

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Life sciences, Clinical medicine, Cell biology, Cancer immunotherapy, Stem cells, Biotechnology, Chimeric antigen receptor T cell, Lymphoma, Cell therapy, Therapy, 7+3

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.

Key Points: 
  • FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.
  • Treatment of the first-ever patient with FT819 ushers in a new era for off-the-shelf CAR T-cell therapy, with the potential to overcome the real-world limitations of existing patient- and donor-derived therapeutic approaches and unlock the full potential of CAR T-cell therapy.
  • FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies.
  • The first patient with relapsed / refractory ALL was enrolled in Regimen A and received a dose of 90 million cells.

Advanced Clinical’s Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

Retrieved on: 
Monday, August 2, 2021
Surgery, Science, Other Health, Veterinary, Nursing, Medical Supplies, Radiology, FDA, Other Science, Pharmaceutical, Diabetes, Research, Optical, Oncology, Mental health, Medical devices, Stem cells, Infectious diseases, Practice Management, Hospitals, Physical therapy, Genetics, Managed care, Fitness & Nutrition, General Health, Dental, Clinical trials, Cardiology, Biotechnology, Alternative medicine, AIDS, Health, Belgrave

Graham Belgrave, Senior Vice President of European Operations at Advanced Clinical, has been recognized by PharmaVOICE magazine as a distinguished leader on the 2021 PharmaVOICE 100 list.

Key Points: 
  • Graham Belgrave, Senior Vice President of European Operations at Advanced Clinical, has been recognized by PharmaVOICE magazine as a distinguished leader on the 2021 PharmaVOICE 100 list.
  • View the full release here: https://www.businesswire.com/news/home/20210802005604/en/
    Advanced Clinical's Graham Belgrave, PharmaVOICE 100 2021 List of Distinguished Leaders (Photo: Business Wire)
    As one of the first European hires at Advanced Clinical in 2017, Graham Belgrave built the companys infrastructure and functional teams outside of North America, contributing to the companys fast growth and development in regions outside of North America.
  • The amazingly powerful culture of servant leadership that permeates through Advanced Clinical is, in my opinion of 37 years in the pharmaceutical industry, truly unique, said Belgrave.
  • PharmaVOICE 100 is an annual list established by PharmaVOICE magazine that recognizes individuals whose inspiration, motivation, and outstanding leadership have made an impact to the life sciences industry.

City of Hope Researchers Develop Miniature Brain Models to Study the Causes of Alzheimer’s Disease and to Test Drugs in Development

Retrieved on: 
Monday, August 2, 2021
Oncology, Health, Hospitals, Other Health, Other Science, Research, Science, Branches of biology, Biology, Stem cells, Life sciences, Organoid, Cerebral organoid, Induced pluripotent stem cell

We, at City of Hope, have created a miniature brain model that uses human stem cell technology to study Alzheimers disease and, hopefully, to help find treatments for this devastating illness.

Key Points: 
  • We, at City of Hope, have created a miniature brain model that uses human stem cell technology to study Alzheimers disease and, hopefully, to help find treatments for this devastating illness.
  • City of Hope researchers were able to model sporadic Alzheimers disease, the most common form of the condition, using brain organoids derived using human induced pluripotent stem cell (hiPSC) technology.
  • Because Alzheimers is a disease of age, the scientists exposed the models to serum to mimic age-associated blood-brain barrier breakdown.
  • Huentelman is a leading expert in the genetic study of Alzheimers disease and was not part of this study.

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Research, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Cancer immunotherapy, Immunotherapy, Virotherapy, Atara

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.
  • Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Companys financial results and provide a corporate update.
  • Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13720150.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Emmes Announces New Role for the Blood and Marrow Transplant Clinical Trials Network

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Clinical medicine, Medicine, Stem cells, Transplantation medicine, Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Hematopoietic stem cell transplantation, Organ transplantation, Bone marrow, Bernhard J. Hering

The study is part of an expanded portfolio of projects conducted under the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Key Points: 
  • The study is part of an expanded portfolio of projects conducted under the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
  • The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts rigorous multi-institutional clinical trials of high scientific merit, focused on improving survival for patients undergoing hematopoietic cell transplantation and/or receiving cellular therapies.
  • The CIBMTR(Center for International Blood and Marrow Transplant Research) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW).
  • The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.

Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs

Retrieved on: 
Friday, July 30, 2021
Health, Stem cells, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Life sciences, Astellas Pharma, Mitsubishi UFJ Financial Group, Biology, Molecular biology, Mitochondrial disease, Mitochondrion

Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., Minovia) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.

Key Points: 
  • Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., Minovia) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
  • View the full release here: https://www.businesswire.com/news/home/20210730005049/en/
    Through this strategic collaboration, Astellas and Minovia aim to accelerate the creation of allogeneic mitochondrial cell therapy programs.
  • Minovia is a leading company in the field of mitochondrial cell therapy that utilizes mitochondrial transfer to deliver healthy mitochondria to a patients diseased cells.
  • The new collaboration with Minovia extends Astellas capabilities in mitochondrial biology, and follow its recent acquisition of Mitobridge, Inc. and Nanna Therapeutics Limited2,3.

Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Stem cells, Clinical trials, Serica, Tocharians, Conference call, NASDAQ, Finance, Service industries

Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m.
  • ET to discuss second quarter 2021 results and provide a general business update.
  • To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6519859.
  • To join the live webcast, please visit the Investors and Media section of the Seres website at www.serestherapeutics.com .

IMV to Participate in the BTIG Virtual Biotechnology Conference

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Stem cells, Pharmaceutical, Oncology, IMV, Fireside chats, The United States, 20th century in the United States

IMV Inc. (IMV or the Corporation) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMVs executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIGs research team.

Key Points: 
  • IMV Inc. (IMV or the Corporation) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMVs executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIGs research team.
  • BTIG Virtual Biotechnology Conference Fireside Chat:
    A link to this presentation will be available under Events, Webcasts and Presentations in the investors section of IMVs website at the above-mentioned time and for approximately 30 days thereafter.
  • All information that addresses activities or developments that we expect to occur in the future is forward-looking information.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, T cells, Stem cells, Regulatory T cell, IPSCS, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.

Key Points: 
  • LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.